Related Experiment Videos
The treatment path in hepatocellular carcinoma
Hashem B El-Serag1, Andrew X Zhu2, Matthew S Johnson3
1Baylor College of Medicine, Houston, Texas.
Clinical Advances in Hematology & Oncology : H&O
|October 17, 2017
Summary
Hepatocellular carcinoma (HCC) treatment varies by stage. Regorafenib offers improved survival for advanced HCC patients previously treated with sorafenib, highlighting advances in systemic therapy.
Area of Science:
- Hepatobiliary Malignancies
- Oncology
- Gastroenterology
Background:
- Hepatocellular carcinoma (HCC) treatment is individualized based on disease stage, liver function, and patient performance status.
- Current treatment modalities include surgery, locoregional therapies, systemic treatments, and supportive care.
- Sorafenib was the sole approved systemic agent for unresectable HCC for a decade.
Purpose of the Study:
- To review the treatment landscape for hepatocellular carcinoma (HCC).
- To highlight the role of systemic therapy, particularly regorafenib, in advanced HCC.
- To emphasize the importance of managing adverse events in systemic cancer treatment.
Main Methods:
- Review of current treatment strategies for HCC.
- Analysis of systemic therapy options for advanced and unresectable HCC.
- Discussion of clinical trial outcomes for sorafenib and regorafenib.
Main Results:
- Surgical resection and ablation are curative for early-stage HCC.
- Transarterial embolization (TACE, TARE) is an option for intermediate-stage HCC.
- Regorafenib demonstrated improved overall survival compared to placebo in patients previously treated with sorafenib.
Conclusions:
- Treatment selection for HCC is multifactorial.
- Regorafenib represents a significant advancement in systemic therapy for advanced HCC.
- Proactive management of treatment-related toxicities is crucial for patients receiving systemic therapy.